Dementia and geriatric cognitive disorders · 2013
A review: treatment of Alzheimer's disease discovered in repurposed agents.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Appleby Brian S, Nacopoulos Dimitrios, Milano Nicholas, Zhong Kate, Cummings Jeffrey L
Аннотация
BACKGROUND/AIMS: Many compounds that have already been approved for alternate diagnoses have been studied in relation to Alzheimer's disease (AD). The purpose of this review is to summarize these studies and discuss the rationale and benefits of repurposing drugs for AD treatment.
METHODS: Studies of drugs related to AD treatment that were relevant to a disease-modifying mechanism of action (MOA) and are already approved by the Food and Drug Administration for non-AD diagnoses were collected from PubMed.
RESULTS: Many drugs already approved for the treatment of other diseases have been studied in relation to AD treatment. Numerous drugs with known toxicity profiles have the potential to be repurposed as a treatment for AD.
CONCLUSION: Known MOA, toxicology, and pharmacodynamic profiles would accelerate the process and increase the odds of finding a more timely disease-modifying treatment for AD.
METHODS: Studies of drugs related to AD treatment that were relevant to a disease-modifying mechanism of action (MOA) and are already approved by the Food and Drug Administration for non-AD diagnoses were collected from PubMed.
RESULTS: Many drugs already approved for the treatment of other diseases have been studied in relation to AD treatment. Numerous drugs with known toxicity profiles have the potential to be repurposed as a treatment for AD.
CONCLUSION: Known MOA, toxicology, and pharmacodynamic profiles would accelerate the process and increase the odds of finding a more timely disease-modifying treatment for AD.
Предметные рубрики MeSH
AgedAlzheimer DiseaseAnti-Asthmatic AgentsAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-SteroidalAnticonvulsantsAntidepressive AgentsAntihypertensive AgentsAntineoplastic AgentsAntiparkinson AgentsAntipsychotic AgentsDrug DiscoveryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMethylene BlueNicotineNicotinic Agonists